Last checked at 5 Jul 2023 09:11
genedrive plc
("genedrive" or the "Company")
Equity Prepayment Facility drawdown
genedrive plc (LSE: GDR), the point of care molecular diagnostics company, today announces a further scheduled £300,000 draw down under the terms of the £5m Equity Prepayment Facility, which was previously announced by the Company on 31 March 2023. Investors have been granted 724,997 warrants equal to 40% of this drawdown divided by the Reference Price of 16.55178 pence. The exercise price of the warrants payable to the Company will be 140% of the Reference Price equating to 23.172492 pence.
Capitalised terms in this announcement shall, unless the context demands otherwise, bear the meanings given to such terms in the announcement of the Facility made via RNS on 31 March 2023.
For further information, please contact:
genedrive plc | +44 (0) 161 989 0245 | ||
David Budd (CEO) / Russ Shaw (CFO) | |||
Peel Hunt LLP - Nominated Adviser, Joint Broker | +44 (0) 20 7148 8900 | ||
James Steel / Oliver Duckworth | |||
finnCap Ltd - Joint Broker | +44 (0) 20 7220 0500 | ||
Geoff Nash / George Dollemore |
| ||
| |||
Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
Paul McManus / Anna Dunphy | Or Genedrive@walbrookpr.com | ||
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.